Mercado global de hibridização in situ – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de hibridização in situ

A incidência do diagnóstico de ISH pode variar muito, dependendo da doença ou condição específica. Por exemplo, no diagnóstico do cancro, as técnicas ISH, como a hibridação fluorescente in situ (FISH), são frequentemente utilizadas para detectar alterações genéticas em tumores, tais como a amplificação de HER2 no cancro da mama ou rearranjos ALK no cancro do pulmão. Nestes casos específicos, a incidência do diagnóstico de ISH dependeria da prevalência destas alterações genéticas na população de doentes.

A Data Bridge Market Research analisa que o mercado global de hibridização in situ, que foi de 1.003,50 milhões de dólares em 2022, dispararia para 2.397,27 milhões de dólares até 2030, e deverá sofrer um CAGR de 11,5% durante o período de previsão. O “Diagnóstico do Cancro” domina o segmento de aplicação do mercado da hibridização in situ devido à crescente procura de melhores métodos de diagnóstico e tratamento. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de hibridização in situ

Market Definition

In situ hybridization refers to a laboratory technique where a probe used, and the probe is made with DNA or RNA. This probe is single-stranded containing moiety that can detect either chemically or radioactively. Then, single-stranded is hybridized and hybridization part comes in. This technique enables precise localization of a specific segment of nucleic acid within a histologic section.

Global In Situ Hybridization Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases, such as cancer, genetic disorder, and neurological disorders, is driving the demand for advanced diagnostic techniques like ISH. ISH enables the detection and analysis of specific genetic markers and alterations associated with these diseases, aiding in accurate diagnosis and personalized treatment strategies.

• Advancements in Molecular Biology and Genomics

The continuous advancements in molecular biology and genomics have expanded our understanding of genetic mechanisms underlying various diseases. ISH techniques have evolved to become more sensitive, specific, and multiplexed, enabling researchers and clinicians to study gene expression patterns, gene fusions, and chromosomal abnormalities with higher precision and accuracy.

• Increasing Research and Development Activities

The growing focus on biomedical research and drug discovery has driven the demand for advanced molecular techniques like ISH. Researchers are using ISH to study gene expression patterns, identify therapeutic targets, and validate drug candidates. The increasing R&D activities in the life sciences sector contribute to the growth of the global ISH market.

• Rising Healthcare Expenditure

Governments and healthcare organizations worldwide are increasing their healthcare expenditure, including investments in advanced diagnostic technologies. The allocation of funds towards improving healthcare infrastructure and access to advanced diagnostic tools is expected to drive the growth of the ISH market.

Opportunities

• Expansion of cancer diagnostics and research

Cancer is a leading application area for ISH, and the growing incidence of cancer worldwide provides a substantial opportunity for the ISH market. ISH techniques play a crucial role in identifying genetic alterations associated with different types of cancer, aiding in accurate diagnosis, prognosis, and treatment selection.

• Advancements in automation and digital pathology

The integration of ISH techniques with automated platforms and digital pathology solutions presents opportunities for increased efficiency, reproducibility, and scalability. Automated ISH systems can streamline the workflow, reduce hands-on time, and improve data analysis. Digital pathology enables remote viewing, sharing, and analysis of ISH results, facilitating collaboration and improving access to expert opinions.

Restraints/Challenges

• High cost of ISH assays

ISH assays can be expensive due to the need for specialized reagents, equipment, and expertise. The high cost of ISH assays can limit their adoption, particularly in resource-constrained settings or regions with limited healthcare budgets.

• Limited availability of skilled personnel

ISH techniques require skilled personnel who have expertise in molecular biology and histopathology. There is a shortage of trained laboratory technicians and pathologists with experience in ISH, which can limit the widespread adoption of ISH in routine diagnostics.

• Regulatory and reimbursement challenges

The regulatory landscape for ISH assays can vary across different regions, which can create challenges for market entry and product approvals. Additionally, reimbursement policies may not always adequately cover the costs of ISH testing, leading to financial constraints for healthcare providers and limited access for patients.

• Competition from alternative molecular techniques

ISH faces competition from other molecular techniques, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and immunohistochemistry (IHC). These techniques offer their own advantages and may be preferred in certain applications, potentially impacting the demand for ISH.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the in situ hybridization market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In October 2021, Leica Biosystems announced the launch of the RNAscope VS Universal HRP Reagent Kit. This kit is designed to enhance the sensitivity of ISH assays, enabling researchers to detect low-abundance RNA targets with high specificity
• In June 2021, Bio-Techne announced the acquisition of Asuragen, a leader in molecular diagnostics and RNA-based technologies. This acquisition strengthens Bio-Techne's capabilities in the field of RNA-based diagnostics, including ISH
• In March 2021, PerkinElmer announced the launch of the Vectra Polaris II Automated Quantitative Pathology Imaging System. This system combines multiplexed immunohistochemistry (IHC) and ISH capabilities, enabling researchers to visualize and quantify multiple biomarkers in tissue samples
• In October 2020, Agilent Technologies introduced the GenetiSure Pre-Screen Kit, a solution for cytogenetic laboratories performing ISH-based pre-screening of clinical samples. This kit streamlines the workflow and improves the efficiency of ISH-based pre-screening for copy number variations.

Global In Situ Hybridization Market Scope

The market is segmented on the basis of technology, application, product, type, and end-user. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Chromogenic In Situ Hybridization (CISH)
• Fluorescence In Situ Hybridization (FISH)

 Application

• Immunology
• Microbiology
• Cancer Diagnostic
• Neuroscience
• Infectious Diseases

Product

• Instruments
• Probes and Kits

Type

• DNA
• RNA

End-User

• Biotechnology/Pharmaceutical Companies
• Academic and Research Institutes
• Molecular Diagnostic Labs

Global In Situ Hybridization Market Regional Analysis/Insights

The global in situ hybridization market is analyzed and market size insights and trends are provided by country, technology, application, product, type, and end-user as referenced above.

The countries covered in the global in situ hybridization market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the global in situ hybridization market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having cancer, immunity diseases, etc.   

Prevê-se que a Ásia-Pacífico testemunhe um crescimento significativo durante o período de previsão de 2023 a 2030 devido ao aumento das iniciativas governamentais para promover os cuidados de saúde, à crescente sensibilização para a saúde entre as pessoas e à crescente procura de tecnologia médica avançada para o tratamento e diagnóstico de doenças como o cancro. , a grande população e a crescente procura de cuidados de saúde de qualidade na região.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e as rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Base instalada de crescimento da infraestrutura de saúde e penetração de novas tecnologias

O mercado global de hibridização in situ também fornece uma análise de mercado detalhada para o crescimento de cada país em termos de despesas de saúde para equipamentos de capital, base instalada de diferentes tipos de produtos para o mercado, o impacto da tecnologia utilizando curvas de segurança e alterações nos cenários regulatórios de saúde e o seu impacto no mercado.

Análise do cenário competitivo e da quota de mercado da hibridização in situ

O panorama competitivo do mercado global de hibridação in situ fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produtos, largura e amplitude do produto, e domínio de aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.

Alguns dos principais players que operam no mercado global de hibridização in situ são:

• Abbott (EUA)
• F. Hoffmann-La Roche Ltd (Suíça)
• Thermo Fisher Scientific Inc.
• Merck KGaA (Alemanha)
• (EUA)
• (EUA)
• Danaher (EUA)
• BioGenex (EUA)
• Advanced Cell Diagnostics, Inc.
• Bio SB (EUA)
• Leica Biosystems Nussloch GmbH (Alemanha)
• Oxford Genetic Technology (Reino Unido)
• Medtronic (Irlanda)
• GENERAL ELECTRIC (EUA)
• Siemens (Alemanha)
• Koninklijke Philips NV (Holanda)
• IMRIS (Canadá)
• NeuroLogica Corp.
• Ziehm Imaging GmbH (Alemanha)

SKU-863